189365-92-2

Upstream product

• 1129-35-7 4-cyanobenzoic acid methyl ester 
• 1444001-63-1 ethyl 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoate 
• 1444001-62-0 ethyl 4-(N'-((ethoxycarbonyl)oxy)carbamimidoyl)benzoate 
• 1227154-44-0 ethyl 4-(N'-hydroxycarbamimidoyl)benzoate 
• 7153-22-2 ethyl 4-cyanobenzoate 
• 184778-33-4 methyl (Z)-4-(N’-hydroxycarbamimidoyl)benzoate 
• 281234-03-5 methyl 4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoate 

Downstream Products

• 340736-41-6 methyl 2-[(2S)-4-[2-(tert-butoxy)-2-oxoethyl]-1-[(2S)-3-(4-methoxyphenyl)-2-[[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoyl]amino]propanoyl]-3-oxopiperazinyl]acetate 
• 1444001-08-4 (S)-ethyl 1-(4-(2-oxo-5-((4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzamido)methyl)oxazolidin-3-yl)phenyl)piperidine-4-carboxylate 
• 1413286-13-1 C₂₅H₂₆Cl₂N₄O₄ 
• 847671-55-0 ethyl (2S)-2-{[(2,4-dimethyl-7-{[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoyl]amino}-2H-1,4-benzoxazin-3(4H)-on-2-yl)carbonyl]amino}-3-{[(4-methylphenyl)sulphonyl]amino}propanoate 
• 847671-80-1 ethyl 5-(7-{[4-(5-oxo-4,5-dihydro-1,2,4-oxadiazol-3-yl)benzoyl]amino}-2H-1,4-benzoxazin-3(4H)-on-4-yl)pentanoate 

Relevant academic research and scientific papers

FACTOR XIa INHIBITORS

The present invention provides a compound of Formula (I) and pharmaceutical compositions comprising one or more said compounds, and methods for using said compounds for treating or preventing thromboses, embolisms, hypercoagulability or fibrotic changes. The compounds are selective Factor XIa inhibitors or dual inhibitors of Factor XIa and plasma kallikrein.

Low molecular weight dual inhibitors of factor Xa and fibrinogen binding to GPIIb/IIIa with highly overlapped pharmacophores

Dual antithrombotic agents acting as anticoagulants and aggregation inhibitors could have substantial advantages over currently prescribed combinations of antithrombotic drugs. Herein, we report compounds with moderate inhibitory activity for factor Xa an

MODULATORS OF ALPHA7 NICOTINIC ACETYLCHOLINE RECEPTORS AND THERAPEUTIC USES THEREOF

The present invention relates to compounds with α7 nAChR agonistic activity, processes for their preparation, pharmaceutical compositions containing the same and the use thereof for the treatment of neurological, psychiatric, cognitive, immunological and inflammatory disorders.

Orally active GPIIb/IIIa antagonists: Synthesis and biological activities of masked amidines as prodrugs of 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]acetic acid

To improve the in vivo potency of the potent GPIIb/IIIa antagonist 2-[(3S)-4-[(2S)-2-(4-amidinobenzoylamino)-3-(4-methoxyphenyl)propanoyl]-3- (2-methoxy-2-oxoethyl)-2-oxopiperazinyl]lacetic acid (4), the amidino group was converted to an oxadiazole ring, thiadiazole ring of substituted amidoxime group. These groups were expected to be metabolized to an amidino group in vivo. The compounds synthesized were evaluated for their potency to inhibit the ex vivo adenosine 5′-diphosphate (ADP)-induced aggregation of guinea pig platelets. Among the compounds examined, the methoxycarbonyloxyamidine 8a exhibited the most potent ex vivo inhibitory activity with a fast onset and prolonged duration of action after oral administration.